-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 13, Betta Pharmaceuticals announced that it had received the "Notice of Acceptance" (acceptance number: CXHS2101028 country, CXHS2101029 country) issued by the State Food and Drug Administration, and the company declared Ensatinib Hydrochloride Capsules (Bemena ®) The application for marketing authorization for "applicable to the treatment of patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC)" has been accepted by the State Food and Drug Administration
Ensatinib Hydrochloride Capsules is a new generation of potent and highly selective ALK inhibitors.
The drug registration application submitted this time is an application for new indications for Ensatinib